目的 以流感病毒血凝素(HA)为作用靶点,筛选新型抗流感多肽药物.方法 通过噬菌体展示技术,从随机十二肽库中筛选HA结合肽,并对筛选获得的多肽进行细胞及鸡胚水平的抗H1N1活性验证.结果 筛选获得了9条HA结合肽,其中H6具有显著的抗病毒活性,其抑制A/FM1/1/47(H1 N1)、A/PR/8/34(H1N1)两株流感病毒致细胞病变的IC50值分别为37.3和48.5 μmol/L,抑制两株病毒在鸡胚内复制的IC50值分别为26.7和33.4 μmol/L.结论 H6有显著的抗H1N1活性,具有开发成新型抗流感病毒药物的潜力.%Objective Using the influenza virus hemagglutinin (HA) as the target to screen for novel anti-influenza polypep-tide drugs. Methods The HA binding peptides were screened out through affinity selection from a 12-peptide phage library, and the anti-H1N1 activity was evaluated at MDCK cell and chicken embryo(ovo). Results Nine HA binding peptides were finally obtained, and the H6 peptide was found having significant antiviral activity against H1N1. Its IC50 against two strains of H1N1, A/FM1/1/47 (H1N1) and A/PR/8/34(H1N1), were 37.3 and 48.5 μmol/L respectively determined by cytopathic effect (CPE)test, and 26.7 and 33.4 μmol/L respectively measured by ovo antiviral experiment. Conclusion These results showed that H6 might be a potential therapeutic drug for H1N1 infection.
展开▼
